Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Praxis Precision Medicines, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.06. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 86 | GlobeNewswire (Europe) | BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES Aktie jetzt für 0€ handeln | |||||
02.06. | Oppenheimer assigns outperform rating to Praxis Precision Medicines stock | 2 | Investing.com | ||
07.05. | Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside | 1 | Benzinga.com | ||
02.05. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 183 | GlobeNewswire (Europe) | BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
02.05. | Praxis Precision Medicines GAAP EPS of -$3.29 | 1 | Seeking Alpha | ||
02.05. | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
02.05. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results | 220 | GlobeNewswire (Europe) | On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025:... ► Artikel lesen | |
02.05. | Praxis Precision Medicines, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.04. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies | 1 | GlobeNewswire (USA) | ||
08.04. | Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings) | 1 | Benzinga.com | ||
03.04. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 278 | GlobeNewswire (Europe) | BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
24.03. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting | 2 | GlobeNewswire (USA) | ||
04.03. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 302 | GlobeNewswire (Europe) | BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
03.03. | Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate | 1 | Benzinga.com | ||
03.03. | Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts | 3 | Benzinga.com | ||
28.02. | Praxis Precision Medicines Plunges 39% After Study Termination Recommendation | 5 | RTTNews | ||
28.02. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Update on Essential3 and Corporate Update | 394 | GlobeNewswire (Europe) | BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
28.02. | Praxis Precision Medicines, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
28.02. | Praxis Precision Medicines, Inc. - 10-K, Annual Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
MODERNA | 23,305 | +0,17 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
AMGEN | 237,00 | +0,11 % | ROUNDUP/Aktien New York Schluss: Gewinne - 'Iran-Angriff eine Gesichtswahrung' | NEW YORK (dpa-AFX) - Der Nahost-Krieg hat am Montag die Richtung an den US-Börsen bestimmt. Die wichtigsten US-Indizes legten am Ende kräftig zu und erreichten kurz vor dem Handelsschluss Tageshöchststände.... ► Artikel lesen | |
NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
BIOGEN | 108,05 | +0,32 % | Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen | |
ILLUMINA | 80,30 | -0,91 % | Code des Lebens entschlüsselt - so geht es weiter! Illumina, PanGenomic Health, Moderna | Erbinformationen sind die Baupläne des Lebens. Schon heute lassen sich mit Hilfe der Genomsequenzierung Informationen gewinnen, die unser Leben verlängern. Das gilt etwa, wenn wir bestimmte Vorprägungen... ► Artikel lesen | |
CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,840 | +1,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
OCUGEN | 0,858 | -1,06 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
COSCIENS BIOPHARMA | 2,680 | -8,22 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
EDITAS MEDICINE | 1,924 | -1,00 % | Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? | ||
BIOCRYST PHARMACEUTICALS | 7,834 | -1,98 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million | -Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones-
-BioCryst plans to use proceeds to... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 14,575 | -0,21 % | Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny |